Home > Insider Trading > Filing (0001415889-24-004903)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1798749	Aerovate Therapeutics Inc.	AVTE	Pharmaceutical Preparations (2834)	831377888

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1868997	Hunter Gillies	C/O Aerovate Therapeutics, Inc. 930 Winter Street, Suite M-500 Waltham MA 02451	Chief Medical Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-02-20	3,489	$1.74	6,740	No	4	M	Direct
Common Stock	Disposition	2024-02-20	2,591	$20.11	4,149	No	4	S	Direct
Common Stock	Disposition	2024-02-20	898	$20.58	3,251	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2024-02-20	2,502	$0.00	2,502	$1.74
Common Stock	Stock Option (Right to Buy)	Disposition	2024-02-20	987	$0.00	987	$1.74

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
3,525		2030-09-03	No	4	M	Direct
8,036		2030-09-03	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.53 to $20.515, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.55 to $20.67, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.